FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2960730055> ?p ?o ?g. }

• W2960730055 abstract "e18543 Background: Mesothelioma is a rare malignancy primarily attributed to asbestos exposure and has limited life expectancy. This study examined patient characteristics, and treatment patterns in commercially insured mesothelioma patients in real world setting. Methods: Patients aged ≥18 yrs with mesothelioma diagnosis were identified using ICD-9 and CPT codes/clinical algorithm between 7/1/2006 and 4/30/2011 from HealthCore Integrated Research Database. Patients with other cancers and without continuous insurance enrollment for ≤ 6-mos before or 12-mos post-diagnosis were excluded. Treatments were grouped into surgery, systemic chemotherapy (Ctx), and best supportive care (BSC) and were assessed descriptively. Results: A total of 184 patients were identified (mean age 64 yrs with 41% patients between 45 and 64 yrs old and 48% ≥65 yrs old, 64% males) with diagnosis of mesothelioma. 61% patients had pleural, 25% had peritoneal and 14% had pericardial disease. Only 10% patients received surgery, 27% received Ctx, while 50% received BSC (including radiation). Among patients who received 1 st line Ctx (mean duration 90 days), almost half of patients received pemetrexed based regimen {pemetrexed + cisplatin (18%) or carboplatin (10%) and pemetrexed alone (20%)} followed by carboplatin monotherapy (42%). Among 41% who received 2 nd line Ctx regimens (mean duration 105 days), most commonly used (65%) were pemetrexed based regimens {pemetrexed alone (35%) and pemetrexed + cisplatin (15%) or carboplatin (15%)} followed by single agent gemcitabine (15%). No patients received vinorelbine (0%). In patients who received Ctx, 35% died before receiving 2nd line Ctx and an additional 15% of patients died before receiving 3rd line Ctx. Only 16% received 3 rd line Ctx. Around 41% patients had at least one emergency room visit and 80% had at least one hospitalization. Conclusions: Mesothelioma is predominant in males and older adults in commercially insured patients in the United States. Systemic chemotherapy remains the main treatment strategy with pemetrexed based therapy being most commonly used regimen. This study highlights limited treatment options and high unmet need in this population." @default.
• W2960730055 created "2019-07-23" @default.
• W2960730055 creator A5003895261 @default.
• W2960730055 creator A5015135453 @default.
• W2960730055 creator A5017071832 @default.
• W2960730055 creator A5042052676 @default.
• W2960730055 creator A5045455127 @default.
• W2960730055 creator A5050501626 @default.
• W2960730055 creator A5061504274 @default.
• W2960730055 date "2013-05-20" @default.
• W2960730055 modified "2023-09-23" @default.
• W2960730055 title "Assessment of treatment patterns in patients with malignant mesothelioma in the United States: A retrospective database analysis." @default.
• W2960730055 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e18543" @default.
• W2960730055 hasPublicationYear "2013" @default.
• W2960730055 type Work @default.
• W2960730055 sameAs 2960730055 @default.
• W2960730055 citedByCount "0" @default.
• W2960730055 crossrefType "journal-article" @default.
• W2960730055 hasAuthorship W2960730055A5003895261 @default.
• W2960730055 hasAuthorship W2960730055A5015135453 @default.
• W2960730055 hasAuthorship W2960730055A5017071832 @default.
• W2960730055 hasAuthorship W2960730055A5042052676 @default.
• W2960730055 hasAuthorship W2960730055A5045455127 @default.
• W2960730055 hasAuthorship W2960730055A5050501626 @default.
• W2960730055 hasAuthorship W2960730055A5061504274 @default.
• W2960730055 hasConcept C126322002 @default.
• W2960730055 hasConcept C142724271 @default.
• W2960730055 hasConcept C143998085 @default.
• W2960730055 hasConcept C167135981 @default.
• W2960730055 hasConcept C2777407522 @default.
• W2960730055 hasConcept C41008148 @default.
• W2960730055 hasConcept C71924100 @default.
• W2960730055 hasConcept C77088390 @default.
• W2960730055 hasConceptScore W2960730055C126322002 @default.
• W2960730055 hasConceptScore W2960730055C142724271 @default.
• W2960730055 hasConceptScore W2960730055C143998085 @default.
• W2960730055 hasConceptScore W2960730055C167135981 @default.
• W2960730055 hasConceptScore W2960730055C2777407522 @default.
• W2960730055 hasConceptScore W2960730055C41008148 @default.
• W2960730055 hasConceptScore W2960730055C71924100 @default.
• W2960730055 hasConceptScore W2960730055C77088390 @default.
• W2960730055 hasLocation W29607300551 @default.
• W2960730055 hasOpenAccess W2960730055 @default.
• W2960730055 hasPrimaryLocation W29607300551 @default.
• W2960730055 hasRelatedWork W1209722778 @default.
• W2960730055 hasRelatedWork W144274770 @default.
• W2960730055 hasRelatedWork W1602757042 @default.
• W2960730055 hasRelatedWork W170240083 @default.
• W2960730055 hasRelatedWork W1984248279 @default.
• W2960730055 hasRelatedWork W1991678913 @default.
• W2960730055 hasRelatedWork W2010761400 @default.
• W2960730055 hasRelatedWork W2031506642 @default.
• W2960730055 hasRelatedWork W2085388707 @default.
• W2960730055 hasRelatedWork W2195573446 @default.
• W2960730055 hasRelatedWork W2373151559 @default.
• W2960730055 hasRelatedWork W2409581956 @default.
• W2960730055 hasRelatedWork W2412912371 @default.
• W2960730055 hasRelatedWork W2469833642 @default.
• W2960730055 hasRelatedWork W2502526717 @default.
• W2960730055 hasRelatedWork W2590199471 @default.
• W2960730055 hasRelatedWork W2946971610 @default.
• W2960730055 hasRelatedWork W2947134238 @default.
• W2960730055 hasRelatedWork W3141969014 @default.
• W2960730055 hasRelatedWork W2299131116 @default.
• W2960730055 isParatext "false" @default.
• W2960730055 isRetracted "false" @default.
• W2960730055 magId "2960730055" @default.
• W2960730055 workType "article" @default.